Angiodysplasia future or investigational therapies: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
Line 1: Line 1:
__NOTOC__
{{Angiodysplasia}}
{{CMG}}; {{AE}} {{NKT}}
==Future or investigational therapies==
In a study, significantly lower levels of Angiopoietin-1 (Ang-1) and [[TNF-α]] were found in patients with small bowel angiodysplasia as compared to the [[control group]].<ref name="pmid28868182">{{cite journal| author=Holleran G, Hussey M, Smith S, McNamara D| title=Assessment of serum angiogenic factors as a diagnostic aid for small bowel angiodysplasia in patients with obscure gastrointestinal bleeding and anaemia. | journal=World J Gastrointest Pathophysiol | year= 2017 | volume= 8 | issue= 3 | pages= 127-132 | pmid=28868182 | doi=10.4291/wjgp.v8.i3.127 | pmc=5561433 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28868182  }} </ref> Despite similar progress in some other studies, the use of chemical markers of angiogenesis as diagnostic tool for angiodysplasia is still at an early stage and would require further research into this area.
In a study, significantly lower levels of Angiopoietin-1 (Ang-1) and [[TNF-α]] were found in patients with small bowel angiodysplasia as compared to the [[control group]].<ref name="pmid28868182">{{cite journal| author=Holleran G, Hussey M, Smith S, McNamara D| title=Assessment of serum angiogenic factors as a diagnostic aid for small bowel angiodysplasia in patients with obscure gastrointestinal bleeding and anaemia. | journal=World J Gastrointest Pathophysiol | year= 2017 | volume= 8 | issue= 3 | pages= 127-132 | pmid=28868182 | doi=10.4291/wjgp.v8.i3.127 | pmc=5561433 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28868182  }} </ref> Despite similar progress in some other studies, the use of chemical markers of angiogenesis as diagnostic tool for angiodysplasia is still at an early stage and would require further research into this area.



Latest revision as of 10:57, 15 October 2021

Angiodysplasia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Angiodysplasia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Angiodysplasia future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Angiodysplasia future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Angiodysplasia future or investigational therapies

CDC on Angiodysplasia future or investigational therapies

Angiodysplasia future or investigational therapies in the news

Blogs on Angiodysplasia future or investigational therapies

Directions to Hospitals Treating Angiodysplasia

Risk calculators and risk factors for Angiodysplasia future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Nikita Singh, M.B.B.S.[2]

Future or investigational therapies

In a study, significantly lower levels of Angiopoietin-1 (Ang-1) and TNF-α were found in patients with small bowel angiodysplasia as compared to the control group.[1] Despite similar progress in some other studies, the use of chemical markers of angiogenesis as diagnostic tool for angiodysplasia is still at an early stage and would require further research into this area.

Further insight into the pathogenesis of angiodysplasia is required for better diagnostic and therapeutic options of this condition.[2]

References

  1. Holleran G, Hussey M, Smith S, McNamara D (2017). "Assessment of serum angiogenic factors as a diagnostic aid for small bowel angiodysplasia in patients with obscure gastrointestinal bleeding and anaemia". World J Gastrointest Pathophysiol. 8 (3): 127–132. doi:10.4291/wjgp.v8.i3.127. PMC 5561433. PMID 28868182.
  2. García-Compeán D, Del Cueto-Aguilera ÁN, Jiménez-Rodríguez AR, González-González JA, Maldonado-Garza HJ (2019). "Diagnostic and therapeutic challenges of gastrointestinal angiodysplasias: A critical review and view points". World J Gastroenterol. 25 (21): 2549–2564. doi:10.3748/wjg.v25.i21.2549. PMC 6558444 Check |pmc= value (help). PMID 31210709.

Template:WS Template:WH